13. Percutaneous intervention for structural heart disease

TAVR for asymptomatic severe aortic stenosis

EARLY TAVR
Objective
to assess the clinical outcomes of early intervention with TAVR as compared to routine clinical surveillance every 6 to 12 months for the treatment of asymptomatic aortic stenosis
Study
prospective, multicentre, open-label randomised trial
Population
patients with severe asymptomatic aortic stenosis and LVEF >50%
Endpoints
composite of death, stroke or unplanned hospitalisation for cardiovascular causes
Conclusion
a strategy of early TAVR was superior to routine clinical surveillance for the treatment of asymptomatic severe aortic stenosis
Généreux et al. NEJM. 2024 28 Oct.
Receive our newsletter


The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved